News

The agreement aims to develop adoptive cell immunotherapies that are intended to destroy metastatic melanoma cells using a patient’s tumor infiltrating lymphocytes. Under the CRADA, the companies will

The tie up allows GNS to use clinical and molecular information from a BMS clinical trial while using its own supercomputer-driven reverse-engineering and forward-simulation (REFS) platform for creating

The trials aim to determine the safety and efficacy profile of the drug in inflammatory disorders. Glenmark has also initiated another global Phase IIb trial with Revamilast in

Watson’s rosuvastatin zinc 5, 10, 20 and 40mg tablets are the generic version of Astrazeneca’s Crestor (rosuvastatin calcium) tablets. Crestor is indicated, as an adjunct to diet, to

The center offers all news, information and research on the five most common cancers in the UK. It also provides access to advice from specialist oncology advisers and

The parntership allows PRECOS to validate RCT’s existing research using its validated patient relevant cancer models like in vitro 2D and 3D assays, in vivo therapeutic evaluations and

CSPN offers specialty pharmacy services including mail distribution, clinical services, therapy management and web-based reporting. MuGard is a viscous, mucoadhesive rinse which provides a protective coating to the

The tie up is focused on leveraging drug discovery platform of Intercept that is based on its proprietary bile acid analog chemistry and expertise targeting TGR5 and other

The company has posted a net loss of $5m for the second quarter of 2011, compared to $2.35m for the same period in 2010. The company’s loss from